Pulmonary nodule cost-effectiveness of therapy

Jump to navigation Jump to search

Pulmonary Nodule Microchapters

Home

Patient Information

Overview

Classification

Causes

Differentiating Pulmonary Nodule from Other Diseases

Epidemiology and Demographics

Screening

Natural history, Complications and Prognosis

Diagnosis

Evaluation of Solitary Pulmonary Nodule

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Case Studies

Case #1

Pulmonary nodule cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pulmonary nodule cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pulmonary nodule cost-effectiveness of therapy

CDC on Pulmonary nodule cost-effectiveness of therapy

Pulmonary nodule cost-effectiveness of therapy in the news

Blogs on Pulmonary nodule cost-effectiveness of therapy

Directions to Hospitals Treating Solitary pulmonary nodule

Risk calculators and risk factors for Pulmonary nodule cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Joanna Ekabua, M.D. [2]

Overview

Navigational bronchoscopy and computed tomography with fine needle aspiration has been shown to be cost-effective in the initial diagnostic strategies of pulmonary nodules.

Cost-effective Therapy

Navigational bronchoscopy and computed tomography with fine needle aspiration diagnostic strategies are most cost-effective compared to either VATS biopsy or 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) scan to diagnose lung cancer in moderate to high-risk pulmonary nodules and resulted in fewer nontherapeutic operations when FDG-PET specificity was < 72%. In regions of the country where specificity is low, FDG-PET scan may not be cost-effective for diagnosis of lung cancer. [1]

References

  1. Deppen SA, Davis WT, Green EA, Rickman O, Aldrich MC, Fletcher S; et al. (2014). "Cost-effectiveness of initial diagnostic strategies for pulmonary nodules presenting to thoracic surgeons". Ann Thorac Surg. 98 (4): 1214–22. doi:10.1016/j.athoracsur.2014.05.025. PMC 4186897. PMID 25087933.